Bryostatin 1
- Generic Name
- Bryostatin 1
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C47H68O17
- CAS Number
- 83314-01-6
- Unique Ingredient Identifier
- 37O2X55Y9E
- Background
Bryostatin 1 has been investigated for the treatment of HIV Infection and Alzheimer's Disease.
- Associated Conditions
- -
- Associated Therapies
- -
Bryostatin 1 Plus Gemcitabine in Treating Patients With Advanced Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-04-24
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 36
- Registration Number
- NCT00004144
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Bryostatin 1 Plus Vincristine in Treating Patients With Recurrent or Refractory HIV-Related Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 12
- Registration Number
- NCT00022555
- Locations
- 🇺🇸
AIDS - Associated Malignancies Clinical Trials Consortium, Rockville, Maryland, United States
Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 65
- Registration Number
- NCT00032188
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer
- Conditions
- Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Blastic Phase Chronic Myelogenous LeukemiaChronic Myelomonocytic LeukemiaChronic Phase Chronic Myelogenous Leukemia
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT00012376
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 32
- Registration Number
- NCT00006942
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
Bryostatin 1 and Cisplatin in Treating Patients With Metastatic or Unresectable Stomach Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 12
- Registration Number
- NCT00006389
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
Bryostatin 1 Plus Cladribine in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-04-24
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 80
- Registration Number
- NCT00003174
- Locations
- 🇺🇸
Josephine Ford Cancer Center at Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸Van Elslander Cancer Center at St. John Hospital and Medical Center, Grosse Pointe Woods, Michigan, United States
🇺🇸Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 19
- Registration Number
- NCT00031694
- Locations
- 🇺🇸
Montefiore Medical Center, Bronx, New York, United States
Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-04-29
- Lead Sponsor
- National Institute on Aging (NIA)
- Target Recruit Count
- 24
- Registration Number
- NCT00003993
- Locations
- 🇺🇸
National Institute on Aging - Baltimore, Baltimore, Maryland, United States
Bryostatin + Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia or Relapsed Indolent Non-Hodgkin's Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2010-02-24
- Lead Sponsor
- Virginia Commonwealth University
- Target Recruit Count
- 54
- Registration Number
- NCT00005580
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸New York Presbyterian Hospital - Cornell Campus, New York, New York, United States
🇺🇸Massey Cancer Center, Richmond, Virginia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.